TY  - JOUR
AU  - Schwarzmueller, Laura J
AU  - Adam, Ronja S
AU  - Moreno, Leandro F
AU  - Nijman, Lisanne E
AU  - Logiantara, Adrian
AU  - Eleonora, Steven
AU  - Bril, Oscar
AU  - Vromans, Sophie
AU  - de Groot, Nina E
AU  - Giugliano, Francesca Paola
AU  - Stepanova, Ekaterina
AU  - Muncan, Vanesa
AU  - Elbers, Clara C
AU  - Lenos, Kristiaan J
AU  - Zwijnenburg, Danny A
AU  - van Eijndhoven, Monique A J
AU  - Pegtel, Dirk Michiel
AU  - van Neerven, Sanne M
AU  - Loayza-Puch, Fabricio
AU  - Dadali, Tulin
AU  - Broom, Wendy J
AU  - Maier, Martin A
AU  - Koster, Jan
AU  - Vermeulen, Louis
AU  - Léveillé, Nicolas
TI  - Identifying colorectal cancer-specific vulnerabilities in the Wnt-driven long non-coding transcriptome.
JO  - Gut
VL  - 74
IS  - 4
SN  - 0017-5749
CY  - London
PB  - BMJ Publishing Group
M1  - DKFZ-2024-02355
SP  - 571-585
PY  - 2025
N1  - 2025 Mar 6;74(4):571-585
AB  - Aberrant Wnt pathway activation is a key driver of colorectal cancer (CRC) and is essential to sustain tumour growth and progression. Although the downstream protein-coding target genes of the Wnt cascade are well known, the long non-coding transcriptome has not yet been fully resolved.In this study, we aim to comprehensively reveal the Wnt-regulated long non-coding transcriptome and exploit essential molecules as novel therapeutic targets.We used global run-on sequencing to define β-catenin-regulated long non-coding RNAs (lncRNAs) in CRC. CRISPRi dropout screens were subsequently used to establish the functional relevance of a subset of these lncRNAs for long-term expansion of CRC.We uncovered that LINC02418 is essential for cancer cell clonogenic outgrowth. Mechanistically, LINC02418 regulates MYC expression levels to promote CRC stem cell functionality and prevent terminal differentiation. Furthermore, we developed effective small interfering RNA (siRNA)-based therapeutics to target LINC02418 RNA in vivo.We propose that cancer-specific Wnt-regulated lncRNAs provide novel therapeutic opportunities to interfere with the Wnt pathway, which has so far defied effective pharmacological inhibition.
KW  - colorectal cancer (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:39562049
DO  - DOI:10.1136/gutjnl-2024-332752
UR  - https://inrepo02.dkfz.de/record/294580
ER  -